Skip to content
DataLookout
Menu

NCT07631637

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment increased: 150 → 360 participants Show 4 more changesShow less
    • Eligibility criteria shortened, about 5 words
    • Trial sites expanded: 16 → 24 locations
    • Secondary endpoints revised (17)
    • Primary endpoint revised
  2. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 8 words
    • Trial sites expanded: 0 → 16 locations
    • Primary and study completion dates: Feb 6, 2029 to Jan 29, 2029
    • Start date changed from estimate of Jul 15, 2026 to Jul 6, 2026
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percent Change from Baseline in Liver Fat by Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF)
Timeframe: At week 52

Secondary (17)

Resolution of MASH with No Worsening of Nonalcoholic Steatohepatitis-Clinical Research Network (NASH-CRN) Fibrosis on Liver Biopsy
Improvement of NASH-CRN Fibrosis Stage (F) by ≥1 with No Worsening of MASH on Liver Biopsy
Percent Change from Baseline in Liver Fat by MRI-PDFF
Achievement of a ≥30% Reduction in Liver Fat by MRI-PDFF Compared to Baseline
Achievement of ≤5% Liver Fat by MRI-PDFF
Show 12 moreShow less
Percent Change from Baseline in Liver Fat by MRI-PDFF for Each Dose Level of ALN-CIDEB Compared to Placebo
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Change from Baseline in FibroScan Controlled Attenuation Parameter (CAP)
Change from Baseline in FibroScan Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE)
Change from Baseline in Aspartate Aminotransferase (AST)
Change from Baseline in Alanine Aminotransferase (ALT)
Change from Baseline in Enhanced Liver Fibrosis (ELF)
Change from Baseline in PRO-C3
Change from Baseline in ADAPT
Change from Baseline in NIS2+
Percent Change from Baseline in Liver Fat by MRI-PDFF in Genetic Subpopulations

Arms and interventions

ALN-CIDEB Dose 1Experimental
ALN-CIDEB Dose 2Experimental
PlaceboPlacebo comparator

Drugs: ALN-CIDEB, Placebo

Sites

24 sites in 3 countries

United States 22, Puerto Rico 1, United Kingdom 1